ICER’s Hall of Shame: The Ten Least Cost-Effective Drugs
Read more here.
MDIC Releases Best Practices for Communicating Benefit, Risk, and Uncertainty for Medical Devices
The Medical Device Innovation Consortium (MDIC) released its report on of Best Practices for Communicating Benefit, Risk, and Uncertainty for [...]
How Medical Affairs Led Medical Education Benefits Patients
New article from the Medical Affairs Professional Society (MAPS) series, ELEVATE, details how patient outcomes are being optimized by Medical [...]
Benefits–Not Just Costs–of Medicines Must Be a Part of Discussion
According to Dr. Robert W. Dubois, Interim President and CEO of NPC, in the context of healthcare costs, the amount [...]
New Study Examines Perspective and Costing in Cost-Effectiveness Analysis
A recent study examined perspective and costing approaches used in cost-effectiveness analyses (CEAs) and the distribution of reported incremental cost-effectiveness [...]
Balancing Research Needs and Big Data Security in Europe
Optimal allocation of limited resources depends upon development of sound evidence demonstrating ‘value for money’ and is thus a critical [...]
HTA in the USA: ICER vs NICE
The Institute for Clinical and Economic Review (ICER) has a reputation for performing high-quality independent health technology assessments (HTAs) in [...]
Big Pharma’s Stealthy Efforts to Undermine ICER
The Institute for Clinical and Economic Review (ICER) wields considerable influence over drug prices by providing analysis of a medicine’s [...]
World’s Most Expensive Prescription Drug Shows Promise in Trial
Episalvan, an orphan drug for a condition called epidermolysis bullosa, is an EMA-approved drug for partial thickness wounds. Shortly after [...]
Applying Adult Learning Principles to Virtual Delivery of Medical Education
Medical education is just one of the many fields radically altered by the COVID-19 pandemic. Medical conferences were either canceled [...]
[Webinar] RWE’s moment: What COVID-19 means for you
The desire for new insights is driving the need for real-world evidence (RWE) across our industry. Join the latest Reuters [...]
New Survey Aims to Find Solutions to Most Pressing Pandemic Challenges
COVID-19 has drastically changed the healthcare landscape, leaving many in crisis mode wondering how to best handle this new reality. [...]
CMS Streamlines Compare Websites With New Care Compare Website
The Centers for Medicare & Medicaid Services (CMS) officially launched Care Compare, a patient-facing website streamlining all CMS Compare websites [...]
Generics Form Essential Bridge to COVID-19 Vaccine
Dan Leonard, the newly named CEO of the Association for Accessible Medicines, believes that generic and biosimilar medicines are an [...]
Addressing Health Inequities Through Traditional Value Frameworks
Join Jason Shafrin, Vice President of Health Economics, and Meena Venkatachalam, Senior Director of Health Economics at PRECISIONheor as they [...]
Clinical Trial Design from a Program Perspective
Join Cytel’s co-founder, Nitin Patel, as he discusses the value in designing clinical trials from a program-level perspective. This webinar [...]
2021 Sternfels Prize Contest Now Open
The $35,000 cash is awarded to the most novel, clinically relevant, and testable ideas in research that aim to reduce [...]
[Webinar] Getting Started With Real World Evidence
Real world evidence (RWE) is becoming increasingly important for stakeholders as they make decisions across product lifecycles. IQVIA has made [...]
Are Virtual Medical Conferences The New Normal?
Thanks to COVID-19, the gradual trend toward virtual platforms has rushed forward at breakneck speed, resulting in a diverse array [...]
Prof. Thomas Rice on Shifting Behavior to Flatten the Curve
In an interview with ISPOR, distinguished professor of the Department of Health Policy and Management at UCLA, Thomas Rice, talks [...]
Jens Gruger Outlines Vision For ISPOR
Jens Gruger assumed the role of President of ISPOR writing: "I have assumed my role as President of ISPOR at [...]
Improving National Clinical Datasets for Health Equity Research
In spite of focused clinical, research, and policy efforts, great disparities in healthcare and outcomes persist. According to researchers, the [...]
No Need for Trump to Eliminate Rebates
In July, the Trump administration announced its intention to eliminate rebates for Medicare Part D drugs to lower prescription drug [...]
[Webinar] 5 Years of ICER – Insights and Impact on Payers
Payers are increasingly reliant on ICER reports for their formulary decision making process. Join this webinar on Tuesday, September 15, [...]
Regulators Need to Plan Now For Allocating COVID-19 Vaccine
Not enough attention is being paid to how exactly a COVID-19 vaccine will be rolled out. What will happen after [...]